<DOC>
	<DOCNO>NCT00974311</DOCNO>
	<brief_summary>This phase 3 study compare clinical benefit MDV3100 versus placebo patient castration-resistant prostate cancer previously treat docetaxel-based chemotherapy .</brief_summary>
	<brief_title>Safety Efficacy Study MDV3100 Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Progressive prostate cancer Medical surgical castration testosterone less 50 ng/dl One two prior chemotherapy regimen . At least one chemotherapy regimen must contain docetaxel ECOG performance status 02 Adequate bone marrow , hepatic , renal function Able swallow study drug comply study requirement Informed consent Metastases brain active epidural disease Another malignancy within previous 5 year Clinically significant cardiovascular disease GI disorder affect absorption</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>MDV3100</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Castration-resistant</keyword>
</DOC>